[ad_1]
US biotech giant Illumina said on Tuesday the company will challenge the European Commission’s prohibition of its $8bn acquisition of Grail — a firm that develops blood-based early cancer detection tests. “It is vital to preserve competition between early cancer detection test-developers at this critical stage of development,” EU commissioner for competition Margrethe Vestager said, going against last week’s ruling by the US federal trade commission.
Join EUobserver today
Become an expert on Europe
Get instant access to all articles — and 20 years of archives.
14-day free trial.
… or subscribe as a group
[ad_2]
Source link